ARCA aims to boost participation by easing stringent enrollment criteria in a study investigating Gencaro in heart failure patients with a favorable response genotype.
FDA Accepts LabCorp's IDE Application for Atrial Fibrillation CDx
NEW YORK (GenomeWeb News) – Arca biopharma today said that Laboratory Corporation of America has told it that the US Food and Drug Administration has accepted LabCorp's investigational device exemption application for a companion diagnostic test for an atrial fibrillation drug under development.
Diaceutics, CAHG Launch Personalized Rx-Focused Marketing, Educational Firm Bioceutics
In Brief This Week: GenDx, KimerDx; Mo Bio Laboratories; Arca biopharma, LabCorp; Perthera
NEW YORK (GenomeWeb News) – Genome Diagnostics (GenDx) announced this week the launch of KimerDx, a spinout of GenDx focused on developing solid organ transplant tests for monitoring disease relapse and transplant rejection. The new firm is led by Doug Bost as managing director.
ARCA Biopharma, a firm developing genetically targeted treatments for cardiovascular diseases, has appointed Ray Woosley to its board of directors.
Apr 28, 2010